4//SEC Filing
Bernards Rene 4
Accession 0001641172-25-002301
CIK 0001335105other
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 10:36 AM ET
Size
10.4 KB
Accession
0001641172-25-002301
Insider Transaction Report
Form 4
Bernards Rene
Director
Transactions
- Award
Options to Purchase Common Stock
2025-03-31+8,045→ 8,045 totalExercise: $1.21From: 2025-03-31Exp: 2030-03-31→ Common (8,045 underlying)
Holdings
- 5,304
Options to Purchase Common Stock
Exercise: $1.30From: 2024-09-30Exp: 2029-09-30→ Common (5,304 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying) - 4,166
Options to Purchase Common Stock
Exercise: $2.33From: 2025-01-20Exp: 2030-01-20→ Common (4,166 underlying) - 4,149
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (4,149 underlying)
Footnotes (1)
- [F1]Effective March 31, 2025, the reporting person was granted stock options to purchase an aggregate of 8,045 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.
Documents
Issuer
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
CIK 0001335105
Entity typeother
Related Parties
1- filerCIK 0001939159
Filing Metadata
- Form type
- 4
- Filed
- Apr 1, 8:00 PM ET
- Accepted
- Apr 2, 10:36 AM ET
- Size
- 10.4 KB